durability

Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study

Papp KA, Jacobs S, Sofen H, Bukhalo M, Muscianisi E, Ma G, Lau G, Bettinger M, Rubio RG, Hitraya E, Blauvelt A; Open-Label Extension study[...]

By afschroeder • October 9, 2025

Efficacy and Safety of Ustekinumab and Vedolizumab for Crohn’s Disease of the Pouch

Park S, Keyashian K, Ho A, Limsui D, Frost S, Vazquez R, Yang E, Ebriani J, Maas L, Parian A, Lazarev M, Parekh N, Sauk[...]

By afschroeder • July 26, 2025